Background: Rosacea is a common chronic skin condition characterized by facial erythema, flushing, papules, and telangiectasia. Understanding the underlying mechanisms and identifying reliable biomarkers are essential for effective diagnosis and management. Dermcidin, an antimicrobial peptide secreted by eccrine sweat glands, has been implicated in various skin disorders due to its role in the innate immune system. Objectives: This review aims to assess the current evidence regarding the assessment of serum dermcidin levels in patients with rosacea. It aims to provide an overview of the association between dermcidin and rosacea, discuss the methodologies used for dermcidin assessment, summarize the clinical findings, and explore the potential implications and limitations of utilizing dermcidin as a biomarker in rosacea. Conclusions: The assessment of serum dermcidin levels in rosacea patients holds promise as a potential diagnostic and monitoring tool. Clinical studies have reported elevated dermcidin levels, altered peptide profiles, or genetic variations in rosacea patients compared to healthy controls. Correlations between dermcidin levels and disease severity, subtypes, or treatment response have been observed.
Background: Rosacea is a common chronic skin condition characterized by facial erythema, flushing, papules, and telangiectasia. Understanding the underlying mechanisms and identifying reliable biomarkers are essential for effective diagnosis and management. Dermcidin, an antimicrobial peptide secreted by eccrine sweat glands, has been implicated in various skin disorders due to its role in the innate immune system. Objectives: This review aims to assess the current evidence regarding the assessment of serum dermcidin levels in patients with rosacea. It aims to provide an overview of the association between dermcidin and rosacea, discuss the methodologies used for dermcidin assessment, summarize the clinical findings, and explore the potential implications and limitations of utilizing dermcidin as a biomarker in rosacea. Conclusions: The assessment of serum dermcidin levels in rosacea patients holds promise as a potential diagnostic and monitoring tool. Clinical studies have reported elevated dermcidin levels, altered peptide profiles, or genetic variations in rosacea patients compared to healthy controls. Correlations between dermcidin levels and disease severity, subtypes, or treatment response have been observed.